Mumbai: Pharma major Lupin Limited (Lupin) announced that it has won the Engineering News-Record’s (ENR) Global Best Project Award of Merit in the Manufacturing category. The award was given to Lupin’s Oral Solid Dosage (OSD) and Injectable Pharmaceutical Manufacturing Facility at Nagpur, India.

The ENR Global Best Projects Awards are annual awards given by ENR globally as part of an annual competition that identifies and honours the best project teams behind outstanding design and construction efforts.

Lupin’s OSD and Injectable facility at Nagpur is Lupin’s latest and most advanced manufacturing unit commissioned in 2018. It is equipped with technologies like an advanced robotic storage and retrieval system and error-free and automated data storage, and the facility is designed to minimise risks associated with cross-contamination using air locks  and multiple process control systems that are automated to keep human intervention to the bare minimum. It is also designed keeping Green building concepts in mind using glass walls for natural light and consideration for LEED® criteria as well as advanced Fire detection and protection systems.

Speaking on the win, Mr. Rajendra B Chunodkar, President – Manufacturing Operations, Lupin Limited said, “We are delighted to receive this global award for our Nagpur OSD and Injectable manufacturing facility. Lupin’s Nagpur facility is equipped with the leading manufacturing technologies and automation and robotic systems that enable safe, compliant and error-free production of complex dosage forms. We remain committed to world-class manufacturing and offering superior quality medicines for our customers.”

About Lupin Limited

 Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company by revenues (31st Dec 2018, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Mar 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Dec 2018, Bloomberg LTM); 5th largest company in the Indian Pharmaceutical Market and 6th largest generic pharmaceutical player in Japan (IQVIA MAT Mar 2019).

For the financial year ended 31st March 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Ph: +91-22 6640 2531 / 9811665000
Email: poojathakran@lupin.com

Or

Arvind Bothra
Head – Investor Relations
Ph: +91-22 6640 8237
Email: arvindbothra@lupin.com

 *Safe Harbor Statement